TY - JOUR
T1 - [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
AU - Harada, Ryuichi
AU - Okamura, Nobuyuki
AU - Furumoto, Shozo
AU - Furukawa, Katsutoshi
AU - Ishiki, Aiko
AU - Tomita, Naoki
AU - Hiraoka, Kotaro
AU - Watanuki, Shoichi
AU - Shidahara, Miho
AU - Miyake, Masayasu
AU - Ishikawa, Yoichi
AU - Matsuda, Rin
AU - Inami, Akie
AU - Yoshikawa, Takeo
AU - Tago, Tetsuro
AU - Funaki, Yoshihito
AU - Iwata, Ren
AU - Tashiro, Manabu
AU - Yanai, Kazuhiko
AU - Arai, Hiroyuki
AU - Kudo, Yukitsuka
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.
AB - Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.
KW - Alzheimer’s disease
KW - Imaging
KW - Neurofibrillary tangles
KW - PET
KW - Tau
KW - [F]THK-5117
UR - http://www.scopus.com/inward/record.url?scp=84938996337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938996337&partnerID=8YFLogxK
U2 - 10.1007/s00259-015-3035-4
DO - 10.1007/s00259-015-3035-4
M3 - Article
C2 - 25792456
AN - SCOPUS:84938996337
VL - 42
SP - 1052
EP - 1061
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 7
ER -